NICE Split Decision: Yes To Docetaxel, No To Paclitaxel For Early-Stage Breast Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
U.K. agency recommends use of Sanofi-Aventis’ Taxotere for early-stage breast cancer one month after prostate cancer nod.
You may also be interested in...
Erbitux and Avastin Aren’t Cost Effective, NICE Finds
Merck KGaA and Roche have 15 days to appeal the ruling regarding metastatic colorectal cancer.
Erbitux and Avastin Aren’t Cost Effective, NICE Finds
Merck KGaA and Roche have 15 days to appeal the ruling regarding metastatic colorectal cancer.
Taxotere Could Get Boost From NICE Prostate Cancer Nod
U.K.’s National Institute for Health & Clinical Excellence recommends coverage of Sanofi-Aventis’ docetaxal for hormone-refractory metastatic prostate cancer.